Thermo Fisher's new EU ultra-cold facility to boost advanced therapies development
This expansion of Thermo Fisher's clinical trial network in Europe will help foster global clinical trial innovation and provide biorepository storage solutions.
Thermo Fisher Scientific Inc., a global leader in serving science, has launched this cutting-edge facility to support pharma and biopharma customers with tailored, end-to-end solutions throughout the clinical supply chain. This includes services for high-value therapies such as cell and gene therapies, biologics, antibodies, and vaccines.
Responding to the growing demand for cell and gene therapy clinical trials in Europe, this facility enhances Thermo Fisher’s market leadership and global CDMO capabilities in bioservices and specialty logistics services, including biorepository solutions and critical material storage. It is designed to meet clinical trial requirements of any scale or phase, leveraging a skilled local workforce to partner with new biotech and established pharmaceutical companies.
"The opening of this cutting-edge facility supporting the development of cell and gene therapies and other biologics, coupled with our proven track record in managing valuable materials, places us in an unmatched position to help our global clients develop innovative therapies," said Molly Flick, vice president and general manager, bioservices & specialty logistics, Thermo Fisher Scientific.
Located just 30 minutes from Amsterdam, the site provides clinical and commercial packaging services for cell and gene therapy products from development to commercialization, along with comprehensive biorepository storage solutions and associated supply chain services. It features 5,000 square meters (54,000 square feet) of ambient to cryogenic storage, cold chain packaging, labeling, distribution, and clinical QP release services.
In line with Thermo Fisher’s commitment to sustainability and its goal of achieving net-zero emissions by 2050, the Bleiswijk site uses 15% solar power, operates completely gas-free, employs eco-friendly electric heat pumps for sustainable heating and cooling, and utilizes advanced heat recovery technology.
Thermo Fisher remains dedicated to providing end-to-end solutions to advance inclusive, impactful clinical research. This new facility in the EU complements recent expansions, including increased biologics manufacturing capacity in St. Louis, a new cell therapy manufacturing facility in San Francisco, and an Innovation Lab in Pennsylvania. For more information on Thermo Fisher’s capabilities, please visit thermofisher.com/patheon.
